[The mechanism and treatment strategies of SARS-CoV-2 mediated inflammatory response]
- PMID: 32840072
- PMCID: PMC10319537
- DOI: 10.7507/1001-5515.202003030
[The mechanism and treatment strategies of SARS-CoV-2 mediated inflammatory response]
Abstract
Since the emergence of novel coronavirus pneumonia in late 2019, it has quickly spread to many countries and regions around the world, causing a significant impact on human beings and society, posing a great threat to the global public health system. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was highly infectious, and some complications emerged rapidly in some patients, including acute respiratory distress syndrome, and multiple organ failure. The virus could trigger a series of immune responses, which might lead to excessive immune activation, thereby bringing about the immune system imbalance of the body. Up to now, there was no specific antiviral drug, and we conjectured that immunomodulatory therapy might play an essential part in the treatment of coronavirus disease 2019 (COVID-19) as adjuvant therapy. Therefore, we analyzed the possible mechanism of immune imbalance caused by the new coronavirus, and summarized the immunotherapeutic means of COVID-19 based on the mechanisms, to provide some reference for follow-up research and clinical prevention and treatment of COVID-19.
自 2019 年年底出现新型冠状病毒肺炎以来,它已迅速波及多个国家和地区,对人类和社会产生了重大影响,对全球公共卫生系统造成了极大的威胁。新型冠状病毒传染性极强,部分感染患者病情进展迅速,可出现急性呼吸窘迫综合征、多器官衰竭等并发症。新型冠状病毒感染后,机体会产生一系列的免疫反应,可能使机体免疫过度激活,造成机体免疫系统失衡。截至目前,尚无针对新型冠状病毒的特效抗病毒药物,免疫调节治疗可能作为辅助治疗手段在新型冠状病毒肺炎的治疗中发挥作用。因此本文主要对新型冠状病毒造成机体免疫失衡可能的机制、免疫调节治疗和其他辅助治疗等进行综述,为后续研究和临床防治工作提供一定参考。.
Keywords: coronavirus disease 2019; immunomodulatory therapy; inflammatory response.
Conflict of interest statement
利益冲突声明:本文全体作者均声明不存在利益冲突。
References
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous